Eribulin in mTNBC Patients

To evaluate the efficacy and safety of Eribulin in patients with advanced breast cancer.

Completed

Looking for future studies?

Key information

Conditions

Breast Cancer Breast Diseases Breast Neoplasms Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Sex eligibility

Female

Study type

Observational

Primary location

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, 200032, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Advanced breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.
Eribulin treatment of advanced breast cancer for at least one cycle, between Dec 2019 and Aug 2020.
Available medical history.

Exclusion criteria

Incomplete medical history.

Treatment and study plan

Primary outcomes

PFS

Time frame: 6 weeks

Progression free survival
Adverse events

Time frame: 6 weeks

Number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)

Sponsors and collaborators

Lead sponsor

Fudan University

Other

Registry information

Official study title

An Observational, Retrospective Study of Eribulin in Advanced Breast Cancer

Important dates

Study start: 2019
Primary completion: 2020
Study completion: 2020
First posted: Sep 9, 2020
Registry last updated: Feb 3, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed